Company registration number: 07516474 Charity registration number: 1165253
Clinical Virology Network
(A company limited by guarantee)
Annual Report and Financial Statements
for the Year Ended 31 May 2025
Clinical Virology Network
Contents
| Reference and Administrative Details | 1 |
|---|---|
| Strategic Report | 2 |
| Trustees' Report | 3 to 5 |
| Independent Examiner's Report | 6 |
| Statement of Financial Activities | 7 |
| Balance Sheet | 8 |
| Statement of Cash Flows | 9 |
| Notes to the Financial Statements | 10 to 15 |
Clinical Virology Network
Reference and Administrative Details
Charity Registration Number 1165253 Company Registration Number 07516474 Registered Office Kings College Hospital South London Specialist Virology Centre 2nd Floor, Cheyne Wing, Bessemer Road London SE5 9RS Independent Examiner Perrigo Consultants Limited Anglo House Worcester Road Stourport on Severn DY13 9AW
Page 1
Clinical Virology Network
Strategic Report for the Year Ended 31 May 2025
The trustees, who are directors for the purposes of company law, present their strategic report for the year ended 31 May 2025, in compliance with s414C of the Companies Act 2006.
Financial review
Principal funding sources
A significant part of the funds for CVN is derived from Annual membership fees.
The strategic report was approved by the trustees of the charity on 22 January 2026 and signed on its behalf by:
......................................... Mark Zuckerman Trustee
Page 2
Clinical Virology Network
Trustees' Report
The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements and auditors' report of the charitable company for the year ended 31 May 2025.
Objectives and activities
Objects and aims
The aim of the network is to promote the interest of clinical virology, and its medical and laboratory practice in the United Kingdom and Ireland. The Newtork provides evidence based and practical virological advice to Government, Chief Medical Officers, the National Heatlh Service and Public Health England on all aspects of viral diseases. The Network also helps to establish and maintain the standards of practice amongst its membership.
Objectives, strategies and activities
The Network promotes a uniform approach to surveillance; a rapid and considered response to virological emergencies; centrally agreed protocols for the management of viral diseases and the best laboratory practice; an education and training resource and undertakes related activities.
The network arranges an annual conference, the conference programmes include plenary sessions with experts presenting work on specific virological topics; trainees presenting scientific papers as well as case histories and specialists presenting information on new diagnostic developments. Bursaries are awarded to more junior clinical scientists and trainees and a small subsidy is also granted to other CVN members attending the conference meeting.
Trustees and officers
The trustees and officers serving during the year and since the year end were as follows:
Trustees: Dr S S Atabani Mark Zuckerman
Structure, governance and management
Nature of governing document
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.
Recruitment and appointment of trustees
The Network has its day to day business conducted by a Chairperson, elected for a period of 3 years from amongst its membership, using a one-member-one-vote system; if no single individual can be agreed on for the post of Chair, two separate Commitee Members may agree to work jointly to fulfil the Chair functions. Members of the Executive Commitee will be elected by vote in the same manner as the Chairperson. A simple majority shall determine the outcome and they shall hold office for a term of 3 years and may stand for re-election.
Induction and training of trustees
Nominations for the post of Chair shall be sought by the Executive Commitee fifteen months before the office becomes vacant. Nominations must be proposed and seconded by members of the Network and the proposed indvidual must agree to be a candidate. The Chair Elect shall serve as deputy to the Chair for a period of 12 months before assuming the role of Chair.
Page 3
Clinical Virology Network
Trustees' Report
Organisational structure
The Clinical Virology Network consists of a linked and co-ordinated group of laboratories distributed in all major centres throughout the UK and Ireland.
The membership of the Executive Committee consists of the Chair, an elected Treasurer, an elected Secretary, three elected members each representing medical virologists, clinical scientists, and biomedical scientists respectively and a representative for the corporate members of the Network.
One part-time appointment of an administrative assistant existed throughout the year.
Relationships with related parties
Members of the Network compromise Consultant Clinical Virologists in Specialist Virology Centres (SVCs) and Reference Laboratories together with those equivalent posts in the Specialist Virology Unites (SVUs); Consultant Clincial Scientists in Clinical Virology; state registered Healthcare Scientists working in Clinical Virology; and specialist Registrars in Clincial Virology.
Membership over 30 SVCs and SVUs and several other specialists and relevant organisations. Retired members are encouraged to continue accessing the website.
The CVN has a number of collaborations and is represented in various professional groups.
Statement of trustees' responsibilities
The trustees (who are also the directors of Clinical Virology Network for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".
Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:
-
select suitable accounting policies and apply them consistently;
-
observe the methods and principles in the Charities SORP;
-
make judgements and estimates that are reasonable and prudent;
-
state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
Page 4
Clinical Virology Network
Trustees' Report
The annual report was approved by the trustees of the charity on 22 January 2026 and signed on its behalf by:
......................................... Mark Zuckerman Trustee
Page 5
Clinical Virology Network
Independent Examiner's Report to the trustees of Clinical Virology Network ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 May 2025.
Responsibilities and basis of report
As the charity’s trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
Independent examiner’s statement
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of Clinical Virology Network as required by section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair view' which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
...................................... Dave Perrigo Association of Chartered Certified Accountants
Anglo House Worcester Road Stourport on Severn DY13 9AW
22 January 2026
Page 6
Clinical Virology Network
Statement of Financial Activities for the Year Ended 31 May 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)
| Note Income and Endowments from: Donations and legacies 3 Total income Expenditure on: Charitable activities 4 Total expenditure Net expenditure Net movement in funds Reconciliation of funds Total funds brought forward Total funds carried forward 11 Note Income and Endowments from: Donations and legacies 3 Other income Total income Expenditure on: Charitable activities 4 Total expenditure Net income Net movement in funds Reconciliation of funds Total funds brought forward Total funds carried forward 11 |
Unrestricted funds £ 50,018 50,018 (55,312) (55,312) (5,294) (5,294) 166,157 160,863 Unrestricted funds £ 59,950 2,111 62,061 (49,880) (49,880) 12,181 12,181 153,976 166,157 |
Total 2025 £ 50,018 |
|---|---|---|
| 50,018 | ||
| (55,312) | ||
| (55,312) | ||
| (5,294) | ||
| (5,294) 166,157 |
||
| 160,863 | ||
| Total 2024 £ 59,950 2,111 |
||
| 62,061 | ||
| (49,880) | ||
| (49,880) | ||
| 12,181 | ||
| 12,181 153,976 |
||
| 166,157 |
All of the charity's activities derive from continuing operations during the above two periods. The funds breakdown for 2024 is shown in note 11.
The notes on pages 10 to 15 form an integral part of these financial statements. Page 7
Clinical Virology Network
(Registration number: 07516474) Balance Sheet as at 31 May 2025
| Note Current assets Debtors 8 Cash at bank and in hand 9 Creditors: Amounts falling due within one year 10 Net assets Funds of the charity: Unrestricted income funds Unrestricted funds Total funds 11 |
2025 £ 27,682 135,702 163,384 (2,521) 160,863 160,863 160,863 |
2024 £ 28,468 141,993 |
|---|---|---|
| 170,461 (4,304) |
||
| 166,157 | ||
| 166,157 | ||
| 166,157 |
For the financial year ending 31 May 2025 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
-
The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
-
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The financial statements on pages 7 to 15 were approved by the trustees, and authorised for issue on 22 January 2026 and signed on their behalf by:
......................................... Mark Zuckerman Trustee
The notes on pages 10 to 15 form an integral part of these financial statements. Page 8
Clinical Virology Network
Statement of Cash Flows for the Year Ended 31 May 2025
| Note Cash flows from operating activities Net cash (expenditure)/income Working capital adjustments Increase in debtors 8 Increase in creditors 10 Net cash flows from operating activities Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at 1 June Cash and cash equivalents at 31 May |
2025 £ (8,111) - 1,821 (6,290) (6,290) 141,992 135,702 |
2024 £ 13,775 (1,787) 4 |
|---|---|---|
| 11,992 | ||
| 11,992 130,001 |
||
| 141,993 |
All of the cash flows are derived from continuing operations during the above two periods.
The notes on pages 10 to 15 form an integral part of these financial statements. Page 9
Clinical Virology Network
Notes to the Financial Statements for the Year Ended 31 May 2025
1 Charity status
The charity is limited by guarantee, incorporated in , and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £Nil towards the assets of the charity in the event of liquidation.
The address of its registered office is: Kings College Hospital South London Specialist Virology Centre 2nd Floor, Cheyne Wing, Bessemer Road London SE5 9RS
These financial statements were authorised for issue by the trustees on 22 January 2026.
2 Accounting policies
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.
Basis of preparation
Clinical Virology Network meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.
Income and endowments
All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.
Expenditure
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Other support costs are allocated based on the spread of staff costs.
Page 10
Clinical Virology Network
Notes to the Financial Statements for the Year Ended 31 May 2025
Taxation
The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.
Fund structure
Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.
3 Income from donations and legacies
| Regular giving and capital donations Total for 2025 Total for 2024 |
Unrestricted funds General £ 50,018 50,018 59,950 |
Total funds £ 50,018 |
|---|---|---|
| 50,018 | ||
| 59,950 |
Page 11
Clinical Virology Network
Notes to the Financial Statements for the Year Ended 31 May 2025
4 Expenditure on charitable activities
| Note Governance costs 5 Total for 2024 |
Unrestricted funds General £ 55,312 49,880 |
Total funds £ 55,312 |
|---|---|---|
| 49,880 |
Total expenditure £
In addition to the expenditure analysed above, there are also governance costs of £55,312 (2024 - £49,880) which relate directly to charitable activities. See note 5 for further details.
5 Analysis of governance and support costs
Governance costs
| Staff costs Wages and salaries Audit fees Other fees paid to auditors Other governance costs Total for 2025 Total for 2024 |
Unrestricted funds General £ 18,858 2,670 33,784 55,312 49,880 |
Total funds £ 18,858 2,670 33,784 |
|---|---|---|
| 55,312 | ||
| 49,880 |
Page 12
Clinical Virology Network
Notes to the Financial Statements for the Year Ended 31 May 2025
6 Staff costs
The aggregate payroll costs were as follows:
| Staff costs during the year were: Wages and salaries |
2025 £ 18,858 |
2024 £ 24,265 |
|---|---|---|
The monthly average number of persons (including senior management / leadership team) employed by the charity during the year expressed as full time equivalents was as follows:
| Average number of employees | 2025 No 1 |
2024 No 1 |
|---|---|---|
No employee received emoluments of more than £60,000 during the year.
Page 13
Clinical Virology Network
Notes to the Financial Statements for the Year Ended 31 May 2025
7 Taxation
The charity is a registered charity and is therefore exempt from taxation.
8 Debtors
| 8 Debtors |
||
|---|---|---|
| Trade debtors Other debtors 9 Cash and cash equivalents Cash at bank Short-term deposits |
2025 £ 24,750 2,932 27,682 2025 £ 135,700 2 135,702 |
2024 £ 24,750 3,718 |
| 28,468 | ||
| 2024 £ 141,991 2 |
||
| 141,993 |
10 Creditors: amounts falling due within one year
| Other taxation and social security Other creditors Accruals 11 Funds Unrestricted funds General Unrestricted funds General |
Balance at 1 June 2024 £ 166,157 Balance at 1 June 2023 £ 153,976 |
Incoming resources £ 50,018 Incoming resources £ 62,061 |
2025 £ (188) 39 2,670 2,521 Resources expended £ (55,312) Resources expended £ (49,880) |
2024 £ - 1,563 2,741 |
|---|---|---|---|---|
| 4,304 | ||||
| Balance at 31 May 2025 £ 160,863 |
||||
| Balance at 31 May 2024 £ 166,157 |
Page 14
Clinical Virology Network
Notes to the Financial Statements for the Year Ended 31 May 2025
12 Analysis of net assets between funds
| Current assets Current liabilities Total net assets Current assets Current liabilities Total net assets 13 Analysis of net funds Cash at bank and in hand Net debt Cash at bank and in hand Net debt |
Unrestricted funds General £ 163,384 (2,521) 160,863 Unrestricted funds General £ 170,461 (4,304) 166,157 At 1 June 2024 £ 141,993 141,993 At 1 June 2023 £ 130,000 130,000 |
Total funds at 31 May 2025 £ 163,384 (2,521) |
|
|---|---|---|---|
| 160,863 | |||
| Total funds at 31 May 2024 £ 170,461 (4,304) |
|||
| 166,157 | |||
| At 31 May 2025 £ 141,993 141,993 At 31 May 2024 £ 130,000 130,000 |
Page 15
Clinical Virology Network
Statement of Financial Activities by fund for the Year Ended 31 May 2025
Unrestricted Funds
| Unrestricted Funds | ||
|---|---|---|
| Income and Endowments from: Donations and legacies Other income Total income Expenditure on: Charitable activities Total expenditure Net (expenditure)/income Net movement in funds Reconciliation of funds Total funds brought forward Total funds carried forward |
Total Unrestricted Funds 2025 £ 50,018 - 50,018 (55,312) (55,312) (5,294) (5,294) 166,157 160,863 |
Total Unrestricted Funds 2024 £ 59,950 2,111 |
| 62,061 | ||
| (49,880) | ||
| (49,880) | ||
| 12,181 | ||
| 12,181 153,976 |
||
| 166,157 |
This page does not form part of the statutory financial statements. Page 16
Clinical Virology Network
Detailed Statement of Financial Activities for the Year Ended 31 May 2025
| Income and Endowments from: Donations and legacies (analysed below) Other income (analysed below) Total income Expenditure on: Charitable activities (analysed below) Total expenditure Net (expenditure)/income Net movement in funds Reconciliation of funds Total funds brought forward Total funds carried forward |
Total 2025 £ 50,018 - 50,018 (55,312) (55,312) (5,294) (5,294) 166,157 160,863 |
Total 2024 £ 59,950 2,111 |
|---|---|---|
| 62,061 | ||
| (49,880) | ||
| (49,880) | ||
| 12,181 | ||
| 12,181 153,976 |
||
| 166,157 |
This page does not form part of the statutory financial statements. Page 17
Clinical Virology Network
Detailed Statement of Financial Activities for the Year Ended 31 May 2025
| Donations and legacies Subscriptions Other income Other income Charitable activities Wages and salaries Website Bursaries Conference expenses Sundry expenses Travel and subsistence Accountancy fees Bad debts written off Bank charges |
Total 2025 £ 50,018 50,018 - - (18,858) (3,692) (11,339) (18,504) - (164) (2,670) - (85) (55,312) |
Total 2024 £ 59,950 |
|---|---|---|
| 59,950 | ||
| 2,111 | ||
| 2,111 | ||
| (24,265) (3,303) (4,558) (5,902) (260) (5,945) (1,590) (3,890) (167) |
||
| (49,880) |
This page does not form part of the statutory financial statements. Page 18